ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do s ...

ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the coverage and reimbursement-related strategies required to support Axogen’s mission ...

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ Form 10-K ____________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri ...

AxoGen (AXGN) Q4 2024 Earnings Call February 25, 2025 05:21 PM ET Company Participants Michael Dale - President, CEO & Board DirectorJens Schroeder Kemp - Chief Marketing OfficerNir Naor - Chief Financial OfficerChris Pasquale - Partner - Medical Devices & SuppliesCaitlin Cronin - DirectorMike Kratky - Senior Managing Director, Medical Devices and Technology Equity ResearchJayson Bedford - Managing Director, Equity Research Conference Call Participants Michael Sarcone - AnalystRoss Osborn - Director, Lead R ...

Core Insights - Axogen, Inc. will hold its Analyst & Investor Day on March 4, 2025, from 9am to 12pm Eastern, featuring key executives discussing business strategies and financial objectives [1][2]. Company Overview - Axogen is a leader in developing and marketing surgical solutions for peripheral nerve injuries, focusing on restoring nerve function and quality of life for patients [4]. - The company offers a comprehensive portfolio of products for peripheral nerve repair, addressing both scheduled non-trauma procedures and emergent trauma procedures [5]. Product Portfolio - Key products include: - Avance® Nerve Graft: A processed human nerve allograft for bridging severed nerves [6]. - Axoguard Nerve Connector®: An aid for tensionless repair of severed nerves [6]. - Axoguard Nerve Protector®: A product to protect damaged nerves and reinforce reconstruction [6]. - Axoguard HA+ Nerve Protector™: A next-generation technology for nerve injury protection [6]. - Avive+ Soft Tissue Matrix™: An amniotic membrane allograft for tissue repair [6]. - Axoguard Nerve Cap®: A product to protect nerve ends and reduce painful neuroma development [6]. - The product portfolio is available in multiple countries, including the United States, Canada, Germany, the United Kingdom, Spain, and South Korea [6].

Core Insights - Axogen, Inc. will hold its Analyst & Investor Day on March 4, 2025, from 9am to 12pm Eastern, featuring key executives discussing business strategies and financial objectives [1][2]. Company Overview - Axogen is a leader in developing and marketing surgical solutions for peripheral nerve injuries, focusing on restoring nerve function and quality of life for patients [4]. - The company offers a comprehensive portfolio of products for both scheduled non-trauma and emergent trauma procedures, addressing various nerve-related conditions [5]. Product Portfolio - Key products include: - Avance Nerve Graft: A processed human nerve allograft for bridging severed nerves [6]. - Axoguard Nerve Connector: An aid for tensionless repair of severed nerves [6]. - Axoguard Nerve Protector: A product to protect and reinforce damaged nerves [6]. - Axoguard HA+ Nerve Protector: A next-generation technology for nerve injury protection [6]. - Avive+ Soft Tissue Matrix: An amniotic membrane allograft for tissue protection during repair [6]. - Axoguard Nerve Cap: A product to protect nerve ends and reduce neuroma development [6]. - The product portfolio is available in multiple countries, including the United States, Canada, Germany, the United Kingdom, Spain, and South Korea [6]. Event Details - A live webcast of the Analyst & Investor Day will be available on Axogen's investor relations website, with a replay accessible for 90 days post-event [3].

ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Financial Results and Business Highlights Fourth quarter revenue was $49.4 million, a 15.1% increase compared to the fourth quarter of 2023.Gross margin was 76.1% for the fou ...

Core Insights - Axogen, Inc. will report its 2024 fourth quarter and full year financial results on February 25, 2025, before market opens, followed by a conference call at 8 a.m. ET [1] - The company specializes in developing and marketing surgical solutions for peripheral nerve injuries, aiming to restore nerve function and improve patients' quality of life [3] Company Overview - Axogen is a leader in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair [3] - The company offers a comprehensive portfolio of products for various applications, including traumatic injuries, oral and maxillofacial surgery, breast reconstruction, and pain treatment [3] - Key products include: - Avance Nerve Graft®: a processed human nerve allograft for bridging severed peripheral nerves [3] - Axoguard Nerve Connector®: an ECM coaptation aid for tensionless repair of severed nerves [3] - Axoguard Nerve Protector®: an ECM product to protect and reinforce damaged peripheral nerves [3] - Axoguard HA+ Nerve Protector™: a next-generation technology for enhancing nerve gliding [3] - Avive+ Soft Tissue Matrix™: an amniotic membrane allograft for tissue protection during repair [3] - Axoguard Nerve Cap®: an ECM product to protect nerve ends and reduce painful neuroma development [3] - Axogen's products are available in multiple markets, including the United States, Canada, the UK, South Korea, and several European and international markets [3]

Core Insights - Axogen, Inc. has appointed Jesse Bishop as Vice President of Regulatory Affairs to lead regulatory strategies for new product development and market approval [1][2][5] - Mr. Bishop brings over 13 years of experience in regulatory strategy and has previously worked with notable companies in the medical field [4][5] - Axogen focuses on innovative surgical solutions for peripheral nerve injuries, aiming to restore nerve function and improve patient quality of life [7][8] Company Overview - Axogen is a leader in the development and commercialization of technologies for peripheral nerve regeneration and repair [7] - The company offers a comprehensive portfolio of products for both scheduled and emergent trauma procedures related to peripheral nerve injuries [8][10] - Axogen's product offerings include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, and Axoguard Nerve Cap, which are available in multiple countries [10] Regulatory Affairs - Mr. Bishop will oversee all aspects of Axogen's regulatory affairs, including product registrations and interactions with regulatory agencies [3] - He will also work on developing regulatory policy in collaboration with external groups such as the Alliance for Regenerative Medicine and the American Association of Tissue Banks [3] Employment Inducement - As part of his employment, Mr. Bishop will receive an equity grant of 45,000 shares of Axogen common stock, with a vesting schedule over four years [6]

Company Performance - AxoGen (AXGN) shares have increased by 27.5% over the past month, reaching a new 52-week high of $18.4 [1] - Year-to-date, AxoGen has gained 9.5%, outperforming the Zacks Medical sector, which declined by 4.5%, and the Zacks Medical - Instruments industry, which returned 6.5% [1] Earnings and Revenue - AxoGen has consistently exceeded earnings expectations, reporting EPS of $0.07 in its last earnings report, surpassing the consensus estimate of $0 [2] - For the current fiscal year, AxoGen is projected to earn $0.31 per share on revenues of $185.2 million, with a year-over-year earnings growth of 251.85% [3] - For the next fiscal year, earnings are expected to rise to $0.48 per share on revenues of $208.47 million, reflecting a year-over-year change of 12.56% [3] Valuation Metrics - AxoGen has a Value Score of D, a Growth Score of A, and a Momentum Score of C, resulting in a VGM Score of B [6] - The stock trades at 57.6X current fiscal year EPS estimates, which is above the peer industry average of 27.6X [6] - On a trailing cash flow basis, AxoGen trades at 5X compared to the peer group's average of 16.8X [6] Zacks Rank - AxoGen holds a Zacks Rank of 2 (Buy), indicating rising earnings estimates and meeting the criteria for potential investment [7] Industry Comparison - The Medical - Instruments industry is positioned in the top 35% of all industries, suggesting favorable conditions for both AxoGen and its peer, Penumbra, Inc. (PEN) [10] - Penumbra, Inc. has a Zacks Rank of 1 (Strong Buy) and is expected to post earnings of $3.86 per share on revenue of $1.19 billion for the current fiscal year [9]